This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Opiant Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Opiant Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 62.6% bzw. 39.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 62.9% pro Jahr wachsen soll.

Wichtige Informationen

62.6%

Wachstumsrate der Gewinne

62.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.9%
Wachstumsrate der Einnahmen	39.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Nov 2022

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Aug 13

Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment

Aug 08

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Aug 05

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Mar 21

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 19

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Nov 17

Opiant Pharmaceuticals: Assessing Recent Insider Buying

Sep 19

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Aug 07

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

Jun 09

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Mar 06

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Mar 05

Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Jan 27

Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003

Dec 14

Opiant Pharmaceuticals receives $50M in convertible debt financing

Dec 10

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:OPNT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	125	38	-7	-3	2
12/31/2024	77	9	-21	-17	2
12/31/2023	37	-23	-31	-27	2
12/31/2022	10	-46	N/A	-16	3
9/30/2022	22	-33	-16	-15	N/A
6/30/2022	39	-20	-10	-10	N/A
3/31/2022	46	-6	-2	-2	N/A
12/31/2021	48	3	2	2	N/A
9/30/2021	44	2	-2	-2	N/A
6/30/2021	37	-1	-2	-2	N/A
3/31/2021	32	-3	-1	-1	N/A
12/31/2020	30	-2	-2	-2	N/A
9/30/2020	27	0	6	6	N/A
6/30/2020	39	10	5	5	N/A
3/31/2020	39	12	6	6	N/A
12/31/2019	41	12	4	4	N/A
9/30/2019	38	1	-3	-3	N/A
6/30/2019	21	-11	-3	-3	N/A
3/31/2019	18	-14	-4	-4	N/A
12/31/2018	14	-21	-1	-1	N/A
9/30/2018	34	-2	-3	-3	N/A
6/30/2018	29	-5	-3	-3	N/A
3/31/2018	30	-3	-5	-5	N/A
12/31/2017	28	3	-9	-9	N/A
10/31/2017	17	2	5	5	N/A
7/31/2017	18	7	6	6	N/A
4/30/2017	15	6	7	7	N/A
1/31/2017	18	9	11	11	N/A
10/31/2016	11	3	0	0	N/A
7/31/2016	10	-8	N/A	-1	N/A
4/30/2016	10	-8	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: OPNT wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.1%).

Ertrag vs. Markt: OPNT wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: OPNT wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: OPNTDie Einnahmen des Unternehmens (39.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: OPNTDie Einnahmen des Unternehmens (39.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von OPNT in 3 Jahren voraussichtlich hoch sein wird

This company has been acquired

Opiant Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 15%

Price target decreased to US$21.50

Consensus revenue estimates fall by 45%

Consensus revenue estimates fall by 13%

Consensus EPS estimates fall by 47%

Consensus revenue estimates increase to US$37.0m

Recent updates

Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose

President recently sold US$102k worth of stock

Consensus revenue estimates increase by 15%

Price target decreased to US$21.50

Opiant Pharmaceuticals, Inc. Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose

Consensus revenue estimates fall by 45%

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Insufficient new directors

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Opiant Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Opiant Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder

Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering Opnt004 for the Treatment of Cannabinoid Hyperemesis Syndrome

Consensus revenue estimates fall by 13%

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene

Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Opiant Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Opiant Pharmaceuticals, Inc. announced that it expects to receive $2.1 million in funding from AptarGroup, Inc., Valois SAS

Independent Director recently sold US$275k worth of stock

Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

Independent Chairman recently bought US$368k worth of stock

Consensus EPS estimates fall by 47%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Opiant Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022

Opiant Pharmaceuticals, Inc. Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone

Insufficient new directors

Opiant Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Investor sentiment improved over the past week

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorated over the past week

President recently sold US$52k worth of stock

Opiant Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Trial of Opnt002

Investor sentiment deteriorated over the past week

Insufficient new directors

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Investor sentiment deteriorated over the past week

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Third quarter 2021 earnings released: EPS US$0.77 (vs US$0.17 in 3Q 2020)

Opiant Pharmaceuticals: Assessing Recent Insider Buying

Independent Chairman recently bought US$174k worth of stock

Independent Director exercised options and sold US$1.6m worth of stock

Second quarter 2021 earnings released: EPS US$0.39 (vs US$0.051 loss in 2Q 2020)

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Consensus revenue estimates increase to US$37.0m

Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from Russell 3000E Value Index

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.40 loss in 1Q 2020)

Opiant Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2021

Independent Director exercised options to buy US$101k worth of stock.

Analysts update estimates

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Full year 2020 earnings released: US$0.44 loss per share (vs US$2.89 profit in FY 2019)

Revenue and earnings beat expectations

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Opiant Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 04, 2021

Independent Director exercised options to buy US$97k worth of stock.

Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

New 90-day high: US$12.96

Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Opiant Pharmaceuticals, Inc. Appoints Craig A. Collard to the Compensation Committee of the Board

New 90-day high: US$9.29

Opiant Pharmaceuticals Announces Additional $3.5 Million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program

Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003

Opiant Pharmaceuticals receives $50M in convertible debt financing

Opiant Pharmaceuticals Announces Appointment of Craig A. Collard as Chairman to Its Board of Directors